| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 12/08/2005 | US20050271661 Synergistic mixture with glucocorticoid receptors antagonist |
| 12/08/2005 | US20050271659 Novel T-cell membrane protein (TIRC7), peptides and antibodies derived therefrom and uses thereof |
| 12/08/2005 | US20050271658 Preventing autoimmune disease |
| 12/08/2005 | US20050271657 Intermittent treatment regime for organ failure |
| 12/08/2005 | US20050271655 Nogo receptor antagonists |
| 12/08/2005 | US20050271654 Antibody purification |
| 12/08/2005 | US20050271653 Methods and devices for targeting a site in a mammal and for removing species from a mammal |
| 12/08/2005 | US20050271652 Treatment of pathologies which escape the immune response, using optimised antibodies |
| 12/08/2005 | US20050271651 Inhibition of bright function as a treatment for excessive immunoglobulin production |
| 12/08/2005 | US20050271650 Method and composition for angiogenesis inhibition |
| 12/08/2005 | US20050271649 Therapeutic adjuvant |
| 12/08/2005 | US20050271647 Chimeric pro-caspases and methods of using same |
| 12/08/2005 | US20050271632 Methods of modulating hair growth |
| 12/08/2005 | CA2822895A1 Influenza hemagglutinin and neuraminidase variants |
| 12/08/2005 | CA2569003A1 Methods and compositions for cancer treatment relating to brca1 brct domain recognition of phosphorylated bach1 |
| 12/08/2005 | CA2568428A1 Ligands binding the complex of urokinase-type plasminogen activator (upa) and its receptor (upar) that inhibit downstream upar interactions: identification and use in diagnosis ortherapy |
| 12/08/2005 | CA2568363A1 Natriuretic compounds, conjugates, and uses thereof |
| 12/08/2005 | CA2568020A1 Influenza hemagglutinin and neuraminidase variants |
| 12/08/2005 | CA2568019A1 Assay for transmissible spongiform encephalopathies |
| 12/08/2005 | CA2568015A1 Influenza hemagglutinin and neuraminidase variants |
| 12/08/2005 | CA2567952A1 Oral anti-protozoiasis vaccines based on transgenic plants |
| 12/08/2005 | CA2567942A1 Hla-a24- or hla-a2-binding peptide of parathyroid hormone-related protein |
| 12/08/2005 | CA2567814A1 Antibodies as t cell receptor mimics, methods of production and uses thereof |
| 12/08/2005 | CA2566861A1 Methods and reagents for the treatment of immunoinflammatory disorders |
| 12/08/2005 | CA2566473A1 Uses of bispecific antibody (biab) coated dendritic cells pulsed with antigens |
| 12/08/2005 | CA2566355A1 Influenza virus vaccine composition and methods of use |
| 12/08/2005 | CA2565330A1 Polypeptides for inducing a protective immune response against staphylococcus aureus |
| 12/08/2005 | CA2565259A1 Soluble lfa-3 polypeptide for treating viral disorders |
| 12/08/2005 | CA2563314A1 Fcyriib-specific antibodies and methods of use thereof |
| 12/08/2005 | CA2562243A1 Treatment of polychondritis and mononeuritis multiplex with anti-cd20 antibodies |
| 12/08/2005 | CA2562037A1 Altered fibronectin-binding protein of staphylococcus aureus |
| 12/07/2005 | EP1602669A1 Antibody against tumor specific antigen as target |
| 12/07/2005 | EP1602668A1 Monoclonal antibodies specific to VEGF receptors and uses thereof |
| 12/07/2005 | EP1602666A1 Novel protein and its dna |
| 12/07/2005 | EP1602664A1 HCV E1 comprising specific disulfide bridges |
| 12/07/2005 | EP1602380A1 Preventive/remedy for diseases in upper digestive tract |
| 12/07/2005 | EP1602371A2 Valproic acid and derivatives for the sensitisation of human cancer cells to increase efficacy in a combination therapy |
| 12/07/2005 | EP1602360A1 Method of obtaining cochlear structures, vaccine compositions, adjuvants and intermediates thereof |
| 12/07/2005 | EP1601967A2 Identification of antigen epitopes |
| 12/07/2005 | EP1601771A1 Subunits of the adenovirus fiber protein and uses thereof as vaccines |
| 12/07/2005 | EP1601770A2 Streptococcus pyogenes antigens |
| 12/07/2005 | EP1601756A2 Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes |
| 12/07/2005 | EP1601695A1 Mcam inhibitors |
| 12/07/2005 | EP1601694A2 Uses of il-23 agonists and antagonists; related reagents |
| 12/07/2005 | EP1601693A2 Novel compositions and methods for the treatment of immune related disease |
| 12/07/2005 | EP1601689A2 Purification process for bacterial cytolysin |
| 12/07/2005 | EP1601688A2 Genes of an otitis media isolate of nontypeable haemophilus influenzae |
| 12/07/2005 | EP1601684A2 Compositions and methods employing alternative reading frame polypeptides for the treatment of cancer and infectious disease |
| 12/07/2005 | EP1601381A2 Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections |
| 12/07/2005 | EP1601376A1 Use of myxoma virus for therapeutic treatment of cancer and chronic viral infection |
| 12/07/2005 | EP1601375A2 Adjuvanted bovine vaccines |
| 12/07/2005 | EP1601374A2 Compositions and methods for diagnosing and treating an inflammation |
| 12/07/2005 | EP1601371A2 Compositions comprising fetal hemoglobin and bacterial endotoxin and optionally additional fetal liver components |
| 12/07/2005 | EP1601333A2 Novel insertion sites in pox vectors |
| 12/07/2005 | EP1601330A2 Antitumor agents comprising a targeting portion and an immune response triggering portion |
| 12/07/2005 | EP1601328A2 Polyvalent immunogen |
| 12/07/2005 | EP1601327A2 Stabilized hbc chimer particles as therapeutic vaccine for chronic hepatitis |
| 12/07/2005 | EP1385886B1 Method for preparing human immunoglobulin concentrates for therapeutic use |
| 12/07/2005 | EP1109579B1 Use of tgf-beta inhibitors for treating cerebral disorders |
| 12/07/2005 | EP1071412B1 Use of quinolinate for treating gastrointestinal disorders |
| 12/07/2005 | EP0996717B1 Immunoprotective influenza antigen and its use in vaccination |
| 12/07/2005 | EP0922105B1 Infectious papillomavirus pseudoviral particles |
| 12/07/2005 | EP0831901B2 Vaccine comprising a polysaccharide antigen-carrier protein conjugate and free carrier protein |
| 12/07/2005 | EP0765163B1 Adjuvant compositions comprising a mineral salt and another immunostimulating compound |
| 12/07/2005 | EP0716701B1 Agent comprising serine-threonine kinase for the diagnostic and therapy of tumors |
| 12/07/2005 | CN1705747A Vector for anti-HPV vaccine and transformed microorganism by the vector |
| 12/07/2005 | CN1705741A Improved immunotherapy |
| 12/07/2005 | CN1705739A T cell used for antigen transduction of antigen delivering system |
| 12/07/2005 | CN1705679A Nucleic acids coding for adhesion factor of group B streptococcus, adhesion factors of group b streptococcus and further uses thereof |
| 12/07/2005 | CN1705678A Therapeutic peptides |
| 12/07/2005 | CN1705492A Recombinant nucleic acid useful for inducing protective immune response against allergens |
| 12/07/2005 | CN1705491A Optimized Fc variants and methods for their generation |
| 12/07/2005 | CN1705438A Antigen-presenting cells for neuroprotection and nerve regeneration |
| 12/07/2005 | CN1704478A Methods for assessing patients with acute myeloid leukemia |
| 12/07/2005 | CN1704475A HBsAg fusion gene with carboxyl-end containing pre S2 immune determinant and protein thereof |
| 12/07/2005 | CN1704119A Oil emulsion inactivated vaccine for parvoviral diseases of pigs |
| 12/07/2005 | CN1704118A Mycobacterium triple nucleic acid vaccine for cattle |
| 12/07/2005 | CN1230538C Immunological reagent specifically interreacting with the extracellular domain of the human zeta chain |
| 12/07/2005 | CN1230536C Tie-2 ligands, methods of making and uses thereof |
| 12/07/2005 | CN1230446C Antibodies and FV fragment recognizing antigen IORC2 |
| 12/07/2005 | CN1230444C Use of HIV polypeptide or peptide or polynucleotide expression construct containing HIV-cell toxicant T-lymphocyte epitope |
| 12/07/2005 | CN1230201C Blood-platelet specific mosaic immune globulin and its using method |
| 12/07/2005 | CN1230184C Prepns. for immunotherapy for cancer having bacterial somatic constituent as active ingredient |
| 12/07/2005 | CN1230152C Hydrogel particle formulations |
| 12/07/2005 | CN1230151C Non-invasive transdermal vaccination |
| 12/06/2005 | US6972322 Polypeptide for use in the treatment of cancerous, angiogenesis, inflammatory shock and autoimmune diseases |
| 12/06/2005 | US6972300 Compounds and compositions for delivering active agents |
| 12/06/2005 | US6972194 culturing cells in envelopes comprising acrylic amide homopolymers, for use in immunization against tumor cells and prophylaxis of diabetes; vaccines |
| 12/06/2005 | US6972179 RRP sequences and knockout mice and uses thereof |
| 12/06/2005 | US6972128 allogeneic immunotherapy; vaccines; immortalization |
| 12/06/2005 | US6972127 administering an effective dose of a polypeptide comprising an immunogenic fragment of A beta (SEQ ID NO:1) and an adjuvant in a regime effective to induce an immune response comprising antibodies to the A beta fragment; Alzheimer's disease |
| 12/06/2005 | US6972125 Comprising a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin; treating various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases |
| 12/06/2005 | CA2285700C Renin-active substance |
| 12/06/2005 | CA2208274C Peptide p277 analogs, and pharmaceutical compositions comprising them for treatment or diagnosis of diabetes |
| 12/06/2005 | CA2079831C Biodegradable polymer composition |
| 12/06/2005 | CA2073282C Human herpesvirus type 6 protein p100, the corresponding dna sequences, their preparation and use |
| 12/01/2005 | WO2005113837A2 Truncated hepatitis c virus ns5 domain and fusion proteins comprising same |
| 12/01/2005 | WO2005113827A2 Construction of live attenuated shigella vaccine strains that express cfa/i antigens (cfab and cfae) and the b subunit of heat-labile enterotoxin (ltb) from enterotoxigenic e. coli |
| 12/01/2005 | WO2005113786A2 Diagnostics and therapeutics for diseases associated with chymase (cma1) |
| 12/01/2005 | WO2005113782A1 Tc-83-derived alphavirus vectors, particles and methods |